DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹2,902 Cr | ₹2,248 Cr | ₹1,755 Cr | ₹1,539 Cr | ₹2,454 Cr |
What is the latest Total Current Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹2,902 Cr |
| Mar2025 | ₹2,248 Cr |
| Mar2024 | ₹1,755 Cr |
| Mar2023 | ₹1,539 Cr |
| Mar2022 | ₹2,454 Cr |
How is Total Current Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,902 Cr | 29.09 | |
| Mar2025 | ₹2,248 Cr | 28.09 | |
| Mar2024 | ₹1,755 Cr | 14.04 | |
| Mar2023 | ₹1,539 Cr | -37.30 | |
| Mar2022 | ₹2,454 Cr | - | |
Compare Total Current Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹254,349.0 Cr | 3.2% | 5.3% | 67.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹427,861.0 Cr | -2% | -6.1% | 12.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹179,153.0 Cr | -1.9% | -2.9% | 32.7% | Stock Analytics | |
| CIPLA | ₹107,406.0 Cr | -1.5% | -4% | -10.6% | Stock Analytics | |
| MANKIND PHARMA | ₹103,049.0 Cr | -0.4% | 7.1% | 2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,362.0 Cr | -2.7% | 4.2% | -1.2% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 3.2% |
5.3% |
67.8% |
| SENSEX | 0.2% |
-4.6% |
-9.6% |
You may also like the below Video Courses